<SEC-DOCUMENT>0001415889-25-022494.txt : 20250820
<SEC-HEADER>0001415889-25-022494.hdr.sgml : 20250820
<ACCEPTANCE-DATETIME>20250820171753
ACCESSION NUMBER:		0001415889-25-022494
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250820
DATE AS OF CHANGE:		20250820

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Mirum Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001759425
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831281555
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-91075
		FILM NUMBER:		251237744

	BUSINESS ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BOULEVARD, SUITE 300
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		650-667-4085

	MAIL ADDRESS:	
		STREET 1:		989 EAST HILLSDALE BOULEVARD, SUITE 300
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Frazier Life Sciences IX, L.P.
		CENTRAL INDEX KEY:			0001720320
		ORGANIZATION NAME:           	
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		601 UNION STREET
		STREET 2:		SUITE 3200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
		BUSINESS PHONE:		206-254-7200

	MAIL ADDRESS:	
		STREET 1:		601 UNION STREET
		STREET 2:		SUITE 3200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98101
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
		<previousAccessionNumber>0001193125-19-204056</previousAccessionNumber>
	    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0001720320</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>





    </filerInfo>
  </headerData>

  <formData>
    <coverPageHeader>
		<amendmentNo>6</amendmentNo>
	      <securitiesClassTitle>Common Stock, par value $0.0001 per share</securitiesClassTitle>
      <dateOfEvent>08/18/2025</dateOfEvent>
	  <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001759425</issuerCIK>
        <issuerCUSIP>604749101</issuerCUSIP>
		<issuerName>MIRUM PHARMACEUTICALS, INC.</issuerName>

        <address>
          <com:street1>989 E Hillsdale Blvd., Suite 300</com:street1>
                    <com:city>FOSTER CITY</com:city>
          <com:stateOrCountry>CA</com:stateOrCountry>
          <com:zipCode>94404</com:zipCode>
        </address>
      </issuerInfo>

	  	  <authorizedPersons>

		<notificationInfo>
			<personName>Steve R. Bailey</personName>
			<personPhoneNum>(206) 621-7200 </personPhoneNum>
				<personAddress>
					<com:street1>601 Union Street, Suite 3200</com:street1>
										<com:city>Seattle</com:city>
					<com:stateOrCountry>WA</com:stateOrCountry>
					<com:zipCode>98101</com:zipCode>
				</personAddress>
		</notificationInfo>
			</authorizedPersons>
	    </coverPageHeader>

	<reportingPersons>


			<reportingPersonInfo>
									<reportingPersonCIK>0001720320</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Frazier Life Sciences IX, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3566912.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3566912.00</sharedDispositivePower>
												<aggregateAmountOwned>3566912.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>7.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001782789</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS IX, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3566912.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3566912.00</sharedDispositivePower>
												<aggregateAmountOwned>3566912.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>7.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001782791</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS IX, L.L.C. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3566912.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3566912.00</sharedDispositivePower>
												<aggregateAmountOwned>3566912.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>7.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>


			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001790879</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Frazier Life Sciences X, L.P.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>168308.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>168308.00</sharedDispositivePower>
												<aggregateAmountOwned>168308.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.3</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001790880</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS X, L.P.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>168308.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>168308.00</sharedDispositivePower>
												<aggregateAmountOwned>168308.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.3</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001790811</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS X, L.L.C.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>168308.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>168308.00</sharedDispositivePower>
												<aggregateAmountOwned>168308.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.3</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>


			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001863769</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Frazier Life Sciences Public Fund, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1574374.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1574374.00</sharedDispositivePower>
												<aggregateAmountOwned>1574374.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>3.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001879466</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLSP, L.P. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1574374.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1574374.00</sharedDispositivePower>
												<aggregateAmountOwned>1574374.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>3.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001879465</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLSP, L.L.C. </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>1574374.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>1574374.00</sharedDispositivePower>
												<aggregateAmountOwned>1574374.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>3.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>


			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001913804</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Frazier Life Sciences Public Overage Fund, L.P.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>940573.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>940573.00</sharedDispositivePower>
												<aggregateAmountOwned>940573.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001963247</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLSP Overage, L.P.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>940573.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>940573.00</sharedDispositivePower>
												<aggregateAmountOwned>940573.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001963248</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLSP Overage, L.L.C.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>940573.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>940573.00</sharedDispositivePower>
												<aggregateAmountOwned>940573.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.9</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>


			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001911592</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Frazier Life Sciences XI, L.P.  </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>





				  				  <fundType>WC</fundType>



				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>544954.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>544954.00</sharedDispositivePower>
												<aggregateAmountOwned>544954.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001911580</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS XI, L.P.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>544954.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>544954.00</sharedDispositivePower>
												<aggregateAmountOwned>544954.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.1</percentOfClass>






			  			  <typeOfReportingPerson>PN</typeOfReportingPerson>








			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001911623</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>FHMLS XI, L.L.C.</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>DE</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>544954.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>544954.00</sharedDispositivePower>
												<aggregateAmountOwned>544954.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>1.1</percentOfClass>












			  			  <typeOfReportingPerson>OO</typeOfReportingPerson>


			  			  <commentContent>The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001341382</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>James N. Topper</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>3735220.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>3735220.00</sharedDispositivePower>
												<aggregateAmountOwned>3735220.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>7.4</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>



			  			  <commentContent>The Aggregate Amount represents (i) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (ii) 163,643 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The Percent of Class is calculated based on 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001365617</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Patrick J. Heron</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>82482.00</soleVotingPower>
												<sharedVotingPower>3735220.00</sharedVotingPower>
												<soleDispositivePower>82482.00</soleDispositivePower>

				<sharedDispositivePower>3735220.00</sharedDispositivePower>
												<aggregateAmountOwned>3735220.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>7.6</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>



			  			  <commentContent>The Aggregate Amount represents (i) 5,703 shares of Common Stock held directly by the Reporting Person, (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person, (iii) 3,566,912 shares of Common Stock held directly by Frazier Life Sciences IX, L.P., and (iv) 163,643 shares of Common Stock held directly by Frazier Life Sciences X, L.P.

The Percent of Class is calculated based on (i) 50,237,647 shares of Common Stock outstanding on August 1, 2025 as set forth in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on August 6, 2025 and (ii) 76,779 shares of Common Stock that are issuable upon the exercise of options held directly by the Reporting Person.</commentContent>

			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001397906</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Albert Cha </reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>0.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.0</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001865123</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>James Brush</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>0.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.0</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>

			<reportingPersonInfo>
									<reportingPersonCIK>0001702527</reportingPersonCIK>

				<reportingPersonNoCIK>N</reportingPersonNoCIK>
				<reportingPersonName>Daniel Estes</reportingPersonName>

								<memberOfGroup>b</memberOfGroup>




				  				  <fundType>AF</fundType>




				<legalProceedings>N</legalProceedings>

								<citizenshipOrOrganization>X1</citizenshipOrOrganization>
												<soleVotingPower>0.00</soleVotingPower>
												<sharedVotingPower>0.00</sharedVotingPower>
												<soleDispositivePower>0.00</soleDispositivePower>

				<sharedDispositivePower>0.00</sharedDispositivePower>
												<aggregateAmountOwned>0.00</aggregateAmountOwned>

				<isAggregateExcludeShares>N</isAggregateExcludeShares>

								<percentOfClass>0.0</percentOfClass>











			  			  <typeOfReportingPerson>IN</typeOfReportingPerson>




			</reportingPersonInfo>
			</reportingPersons>


	<items1To7>
		<item1>
			<securityTitle>Common Stock, par value $0.0001 per share</securityTitle>
			<issuerName>MIRUM PHARMACEUTICALS, INC.</issuerName>

			<issuerPrincipalAddress>
			 <com:street1>989 E Hillsdale Blvd., Suite 300</com:street1>
			  			  <com:city>FOSTER CITY</com:city>
			  <com:stateOrCountry>CA</com:stateOrCountry>
			  <com:zipCode>94404</com:zipCode>
			</issuerPrincipalAddress>

						<commentText>This Amendment No. 6 ("Amendment No. 6") to Schedule 13D amends the statement on Schedule 13D filed on July 26 2019 (the "Original Schedule 13D") as amended on April 29, 2020, December 18, 2020, August 16, 2022, April 14, 2023 and September 5, 2023 (the "Prior Amendments", and together with the Original Schedule 13D and this Amendment No. 6, the "Schedule 13D"). Except as otherwise specified in this Amendment No. 6, all items in the Original Schedule 13D, as amended by the Prior Amendments, are unchanged. All capitalized terms used in this Amendment No. 6 and not otherwise defined herein have the meanings ascribed to such terms in the Original Schedule 13D, as amended by the Prior Amendments.</commentText>
					</item1>




				<item5>
			 <percentageOfClassSecurities>The information contained in Rows 7, 8, 9, 10, 11, and 13 of each Reporting Person's cover page to this Schedule 13D (including the footnotes thereto) is incorporated by reference into this Item 5.

FLSPF directly holds 1,574,374 shares of Common Stock of the Issuer (the "FLSPF Shares"). FHMLSP, L.P. is the general partner of FLSPF and the general partner of FHMLSP, L.P. is FHMLSP, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

FLSPOF directly holds 940,573 shares of Common Stock of the Issuer (the "FLSPOF Shares"). FHMLSP Overage, L.P. is the general partner of FLSPOF and the general partner of FHMLSP Overage, L.P. is FHMLSP Overage, L.L.C., which is managed by an investment committee of four that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLSPOF, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

FLS IX directly holds 3,566,912 shares of Common Stock of the Issuer (the "FLS IX Shares"). FHMLS IX, L.P. is the general partner of FLS IX and FHMLS IX, L.L.C. is the general partner of FHMLS IX, L.P. Heron and Topper are the members of FHMLS IX, L.L.C. and therefore share voting and investment power over the FLS IX Shares.

FLS X directly holds 168,308 shares of Common Stock of the Issuer (the "FLS X Shares"). FHMLS X, L.P. is the general partner of FLS X and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Heron and Topper are the members of FHMLS X, L.L.C. and therefore share voting and investment power over the FLS X Shares.

FLS XI directly holds 544,954 shares of Common Stock of the Issuer (the "FLS XI Shares"). FHMLS XI, L.P. is the general partner of FLS XI and the general partner of FHMLS XI, L.P. is FHMLS XI, L.L.C., which is managed by an investment committee of three that acts by majority vote. Accordingly, no members of such committee are attributed beneficial ownership of the securities directly held by FLS XI, and this Schedule 13D corrects any previous attribution to, and overstatement of beneficial ownership by, such members as reflected in any prior Statements.

Except as specifically stated herein, the filing of this Schedule 13D shall not be construed as an admission that any Reporting Person or any of the foregoing is, for the purposes of Section 13(d) and/or Section 13(g) of the Act or otherwise, the beneficial owner of any securities covered by this Schedule 13D or a member of a "group" with any other person.</percentageOfClassSecurities>														</item5>


				<item7>
			<filedExhibits>Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13D/A filed on September 5, 2023)</filedExhibits>
		</item7>

	</items1To7>

<signatureInfo>

	<signaturePerson>
		<signatureReportingPerson>Frazier Life Sciences IX, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P., GP of Frazier Life Sciences IX, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS IX, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS IX, L.L.C., GP of FHMLS IX, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS IX, L.L.C. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS IX, L.L.C.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Frazier Life Sciences X, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P., GP of Frazier Life Sciences X, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS X, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS X, L.L.C., GP of FHMLS X, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS X, L.L.C.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS X, L.L.C.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Frazier Life Sciences Public Fund, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P., GP of Frazier Life Sciences Public Fund, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLSP, L.P. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>Steve R. Bailey, CFO of FHMLSP, L.L.C., GP of FHMLSP, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLSP, L.L.C. </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLSP, L.L.C.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Frazier Life Sciences Public Overage Fund, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P., GP of Frazier Life Sciences Public Overage Fund, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLSP Overage, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C., GP of FHMLSP Overage, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLSP Overage, L.L.C.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLSP Overage, L.L.C.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Frazier Life Sciences XI, L.P.  </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P., GP of Frazier Life Sciences XI, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS XI, L.P.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C., GP of FHMLS XI, L.P.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>FHMLS XI, L.L.C.</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, CFO of FHMLS XI, L.L.C.</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>James N. Topper</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, Attorney-in-Fact for James N. Topper, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Patrick J. Heron</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, Attorney-in-Fact for Patrick J. Heron, pursuant to a Power of Attorney, a copy of which was filed with the SEC on July 31, 2017</title>
				<date>03/06/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Albert Cha </signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, Attorney-in-Fact for Albert Cha, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>James Brush</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, Attorney-in-Fact for James Brush, pursuant to a Power of Attorney, a copy of which was filed with the SEC on August 16, 2021</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>

	<signaturePerson>
		<signatureReportingPerson>Daniel Estes</signatureReportingPerson>

					<signatureDetails>
				<signature>/s/ Steve R. Bailey</signature>
				<title>By Steve R. Bailey, Attorney-in-Fact for Daniel Estes, pursuant to a Power of Attorney, a copy of which was filed with the SEC on April 18, 2022</title>
				<date>08/20/2025</date>
			</signatureDetails>

	</signaturePerson>



</signatureInfo>
</formData>


</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
